SEARCH

SEARCH BY CITATION

References

  • 1
    Bousquet J, Malling HJ, Lockey RF. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53(Suppl. 54):115.
  • 2
    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:12551261.
  • 3
    Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy. 2000;55:522530.
  • 4
    Nelson HS. Advances in upper airway disease and allergen immunotherapy. J Allergy Clin Immunol 2003;111:793798.
  • 5
    Canonica GW, Passalacqua G Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437448.
  • 6
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:412.
  • 7
    Bousquet J, Van Cauwenberge P. Allergic Rhinitis and its Impact on Asthma. J Allergy Clin Immunol 2001;108(5 Suppl.):S146S150.
  • 8
    Joint Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2003;90(Suppl. 1):140.
  • 9
    Passalacqua G, Canonica GW. Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy 2002;57:275276.
  • 10
    Pajno G, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:13921397.
  • 11
    Purello D'Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Paramiani S et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:12951302.
  • 12
    Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99:450453.
  • 13
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251256.
  • 14
    Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114:851857.
  • 15
    Altman DG, Bland JM. How to randomise. BMJ 1999;319:703704.
  • 16
    Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials. Drug Inf J 1990;24:541548.
  • 17
    MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ 1998;317:362363.
  • 18
    European MEdicine Agency. Points to consider on adjustment for baseline covariates. Publication 2003; CPMP/EWP 2863/99.
  • 19
    Durham SR, Bauchau V. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005;60:350353.
  • 20
    Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham SR et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003;58:192197.
  • 21
    Oude Elberink JN, De Monchy JG, Van Der Heide S, Guyatt GH, Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174182.
  • 22
    Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study. Allergy 1999;54:249260.
  • 23
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. UK Immunotherapy Study Group Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:319325.
  • 24
    Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martin-Garcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-HErranz J. Immunotherapy with a depigmented glutaraldehyde polymerized extract: changes in quality of life. Clin Exp Allergy 2005;35:572578.
  • 25
    Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461472.
  • 26
    Gidaro G, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35: 565571.
  • 27
    Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004;93:312.
  • 28
    Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling H-J, Valovirta E. EAACI Practice Parameters for immunotherapy. Allergy 2006;61(Suppl. 82):s1s20.
  • 29
    Bloom BS, De Pouvourville N, Libert S. Classic or Bayesian research design and analysis. Does it make a difference? Int J Technol Assess Health Care 2002;18:120126.
  • 30
    Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc 1937;32:675701.
  • 31
    Box GEP, Jenkins GM. Time series analysis. Forecasting and control. Sal Francisco: Holden-Day, 1976.
  • 32
    Brunner E, Domhof S, Langer S. Nonparametric analysis of longitudinal data in factorial experiments. New York, John Wiley & Sons, 2002.
  • 33
    Malling HJ. Criteria for clinical efficacy – readout and monitoring of clinical studies. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2003;94:119123.
  • 34
    Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338344.
  • 35
    Khinchi L, Poulsen LF, Carat F, Andre C, Hansen AB, Mallung HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomised, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:4553.
  • 36
    Malling HJ. Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. Curr Opin Allergy Clin Immunol 2004;4:539542.
  • 37
    Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998;101:163170.
  • 38
    Potter PC. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol 2005;95:175180.
  • 39
    Clarke SA, Eiser C. The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2004;22:66.